Mounjaro and Bupropion Interaction: What Patients and Prescribers Need to Know

How Tirzepatide Is Metabolized (and Why CYP2D6 Is Not the Issue)

Tirzepatide does not rely on cytochrome P450 enzymes for its clearance. The FDA prescribing information for Mounjaro states that tirzepatide is eliminated primarily through proteolytic cleavage of the peptide backbone, fatty-acid moiety beta-oxidation, and amide hydrolysis, with renal excretion of fragments playing a secondary role. [1] Because tirzepatide is not a CYP substrate, bupropion's strong CYP2D6 inhibition has no direct effect on tirzepatide plasma concentrations.

This is a meaningful distinction. Many clinicians initially flag the combination because bupropion is one of the most potent CYP2D6 inhibitors in common use, capable of converting extensive metabolizers into phenotypic poor metabolizers. [2] That inhibition matters a great deal for the rest of a patient's medication list, but it does not change how tirzepatide behaves.

What Bupropion Does to CYP2D6

Bupropion and its active metabolite hydroxybupropion inhibit CYP2D6 in a time-dependent and concentration-dependent manner. [2] A patient taking bupropion 300 mg/day who is also on a CYP2D6-sensitive agent such as metoprolol, nortriptyline, or codeine will experience meaningfully higher plasma concentrations of that third drug.

The FDA bupropion label carries an explicit warning: co-administration with drugs that are metabolized by CYP2D6 should prompt consideration of reduced doses of the CYP2D6-sensitive agent, especially when bupropion is initiated or discontinued. [3] Prescribers adding tirzepatide to a patient already on bupropion must audit the entire medication list for CYP2D6 substrates before starting.

Why Tirzepatide's GI Effects Create an Indirect Risk

Tirzepatide's most common adverse effects are gastrointestinal: nausea, vomiting, and diarrhea. In the SURMOUNT-1 trial (N=2,539), nausea occurred in 31.0% of participants receiving tirzepatide 15 mg, vomiting in 16.4%, and diarrhea in 22.1%. [4] Persistent vomiting or diarrhea can produce dehydration and hyponatremia, both of which are established risk factors for lowering the clinical seizure threshold.

Bupropion carries a dose-dependent seizure risk that is already encoded in its black-box warning. The incidence of seizures with bupropion at doses up to 450 mg/day is approximately 0.1%, rising sharply if plasma concentrations increase from CYP2D6 inhibition by other drugs or from pharmacokinetic variability. [3] Dehydration-driven electrolyte disturbances in a patient on bupropion compound that baseline seizure risk in a clinically meaningful way.

The Pharmacodynamic Concern: Seizure Threshold

Bupropion's Seizure Mechanism

Bupropion inhibits neuronal reuptake of norepinephrine and dopamine. At high plasma concentrations, this NDRI activity appears to reduce GABAergic inhibition and increase excitatory neurotransmission, which is the proposed mechanism for its seizure-lowering effect on threshold. [3] The risk is highest in patients who already have a history of seizures, are withdrawing from alcohol or benzodiazepines, or have eating disorders with purging behavior, partly because electrolyte derangements from purging mirror those produced by severe GI intolerance to GLP-1-based therapies.

How Tirzepatide Fits Into That Picture

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA in May 2022 for type 2 diabetes. [1] It produces weight loss through appetite suppression, slowed gastric emptying, and augmented insulin secretion. [5] None of these mechanisms directly affect seizure threshold. The indirect pathway is the one that matters: if a patient loses 2 to 3 liters of fluid from vomiting during the titration phase and serum sodium drops to 128 mEq/L, the seizure risk from bupropion may rise from theoretical to clinically significant.

The 2023 American Diabetes Association Standards of Care note that GLP-1 receptor agonist-based therapies require attention to volume status, particularly in older adults and those on concomitant diuretics. [6] The same principle applies to GIP/GLP-1 dual agonists like tirzepatide.

Patient Populations at Highest Risk

Patients with any of the following characteristics warrant the most careful evaluation before combining tirzepatide and bupropion:

• History of a seizure disorder or unprovoked seizure
• Active bulimia nervosa or anorexia nervosa (both eating disorders are listed as contraindications to bupropion in the FDA label) [3]
• Hyponatremia at baseline (sodium <135 mEq/L)
• Concurrent use of alcohol, benzodiazepines, or other agents that lower seizure threshold
• Age over 65 with already limited fluid reserve

CYP2D6 Inhibition: The Third-Drug Problem

Why the Rest of the Medication List Matters

The most clinically actionable risk from combining Mounjaro and bupropion is not the two-drug interaction itself. It is the hidden three-drug interaction that bupropion creates whenever a patient is also on a CYP2D6-sensitive medication.

Common CYP2D6 substrates that appear frequently on the medication lists of patients seeking GLP-1 therapy include: metoprolol (beta-blocker used for cardiovascular protection), tricyclic antidepressants such as nortriptyline and amitriptyline, antipsychotics including risperidone and haloperidol, opioids including tramadol and codeine, and tamoxifen. [2] Bupropion can raise plasma concentrations of these agents by 2- to 5-fold. Adding tirzepatide does not change those concentrations directly, but the clinical context shifts: a patient starting tirzepatide for weight management may be adding bupropion at the same time (since the combination bupropion-naltrexone is approved for weight loss as Contrave), making this a clinically common three-drug scenario.

Contrave and Tirzepatide: A Special Case

Bupropion 90 mg / naltrexone 8 mg (Contrave) is an FDA-approved weight-loss combination. [7] Some patients or prescribers may consider adding Contrave to tirzepatide for additive weight loss. No randomized trial has examined this specific triple combination. The pharmacodynamic concern about seizure threshold remains; the CYP2D6 inhibition from the bupropion component of Contrave is present even at lower bupropion doses. Prescribers considering this approach should document a shared decision-making conversation that addresses the lack of prospective safety data.

Monitoring Protocol for Patients on Both Agents

Before Starting Tirzepatide in a Patient Already on Bupropion

1. Obtain a baseline metabolic panel including serum sodium, potassium, and creatinine.
2. Document current seizure history; if present, consult neurology before initiating tirzepatide.
3. Screen the full medication list for CYP2D6 substrates using the FDA Drug Interactions Table or the Indiana University P450 Drug Interaction Table. [2]
4. If a CYP2D6-sensitive drug is on the list, consider dose adjustment before starting tirzepatide, since added GI side effects may unpredictably reduce absorption of oral agents during titration.
5. Confirm the patient does not have an active eating disorder diagnosis, which is a bupropion contraindication independent of tirzepatide. [3]

During Tirzepatide Titration (Weeks 1 Through 20)

Tirzepatide is titrated from 2.5 mg weekly to a maintenance dose of 5 mg, 10 mg, or 15 mg weekly over approximately 20 weeks. [1] GI side effects are most prominent during dose escalation steps. Monitoring during this period should include:

• Symptom check at each dose-escalation visit: frequency of vomiting and diarrhea, estimated fluid loss
• Repeat electrolytes if vomiting occurs on more than 3 consecutive days or if the patient reports dizziness or muscle cramps
• Patient counseling to call the clinic before any dose of bupropion is changed, since dose changes alter CYP2D6 inhibition intensity

Long-Term Steady-State Monitoring

Once a patient reaches a stable tirzepatide dose and GI side effects have attenuated, the CYP2D6 interaction remains constant as long as bupropion dose is unchanged. The FDA Mounjaro label does not list bupropion as a drug of concern for tirzepatide. [1] The monitoring burden shifts to whichever CYP2D6-sensitive co-medications are present.

What the FDA Labels Say

Mounjaro (Tirzepatide) FDA Label

The Mounjaro prescribing information does not identify any specific named drug interaction with bupropion. [1] The label does note that tirzepatide slows gastric emptying and may reduce the absorption rate of orally administered drugs, particularly in the first several hours after injection. For drugs with narrow therapeutic windows, the label recommends monitoring. Bupropion is not a narrow-therapeutic-index drug by FDA definition, and its sustained-release formulation reduces peak concentration variability, making gastric-emptying-related absorption changes less clinically significant.

Bupropion FDA Label

The bupropion prescribing information carries multiple relevant warnings. [3] The black-box warning covers neuropsychiatric events and seizure risk. The drug interactions section identifies bupropion as a CYP2D6 inhibitor and states: "If bupropion is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index." [3] The label also identifies alcohol use, eating disorders, abrupt discontinuation of benzodiazepines, and prior seizure history as factors that further increase seizure risk.

Gastric Emptying and Bupropion Absorption

Tirzepatide slows gastric emptying, an effect shared with GLP-1 receptor agonists like semaglutide. A pharmacokinetic study of oral semaglutide found that gastric emptying delay altered the absorption of co-administered medications in some subjects. [8] Tirzepatide's effect on gastric emptying is present but attenuates over time as tachyphylaxis develops at the GLP-1 receptor. [5]

Bupropion's extended-release formulations (Wellbutrin XL, Wellbutrin SR) are designed to release drug slowly over 12 to 24 hours. A moderate delay in gastric emptying may shift the absorption curve but is unlikely to reduce the area under the curve (AUC) in a clinically meaningful way for most patients. Immediate-release bupropion is no longer widely prescribed for depression, but if a patient is on it, the interaction with tirzepatide-driven gastric delay is theoretically larger and monitoring for subtherapeutic antidepressant effect during the first 4 to 8 weeks of tirzepatide use is reasonable.

Patient Counseling Points

Patients taking Mounjaro and bupropion together should receive clear, specific instructions. The following points cover the highest-yield topics:

• Drink at least 2 liters of water daily, and replace fluids lost to nausea or vomiting promptly.
• Report any new neurological symptoms (unusual tremor, confusion, vision changes, muscle twitching) to the prescribing clinic immediately.
• Do not stop bupropion abruptly; abrupt discontinuation can itself lower the seizure threshold during a transition period.
• If vomiting persists for more than 48 hours at any tirzepatide dose escalation step, contact the clinic before continuing to the next dose level.
• Alcohol use should be minimized or eliminated, since alcohol compounds bupropion's seizure risk. The bupropion FDA label states that alcohol consumption should be minimized. [3]
• Any pharmacist filling a new prescription should be told about both medications so that CYP2D6 interactions with any new drug can be screened before dispensing.

Clinical Evidence and Relevant Trial Data

No randomized controlled trial has specifically examined the tirzepatide-bupropion combination as a primary endpoint. The evidence base for each drug individually is strong.

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 20.9% mean body weight reduction at 72 weeks versus 3.1% with placebo (P<0.001). [4] Serious adverse events occurred in 6.3% of the tirzepatide group, with gastrointestinal events being the most common reason for discontinuation.

The SURPASS-2 trial (N=1,879) compared tirzepatide with semaglutide 1 mg in type 2 diabetes. Tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide (P<0.001), with nausea rates of 24% for tirzepatide versus 17.4% for semaglutide. [9] Higher nausea rates translate to higher dehydration risk, reinforcing the importance of hydration monitoring when bupropion is co-prescribed.

For bupropion's CYP2D6 inhibition, a pharmacokinetic study by Hesse et al. Found that bupropion 150 mg twice daily increased desipramine AUC by approximately 5-fold in healthy volunteers, confirming the potency of CYP2D6 inhibition at therapeutic doses. [10] This is among the strongest CYP2D6 inhibition effects observed with any commercially available antidepressant.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy notes that combination pharmacotherapy for obesity should account for drug interactions before initiation, with particular attention to agents affecting CYP enzymes or seizure threshold. [11]

Is There Any Benefit to This Combination?

Patients who are already on bupropion for depression or smoking cessation and who need to start tirzepatide for diabetes or weight management do not need to stop bupropion solely because of this interaction. The combination is used clinically. The key is informed risk management.

For patients seeking additive weight loss from both agents simultaneously, the evidence base for tirzepatide monotherapy is already strong enough that the marginal benefit of adding bupropion specifically for weight loss (rather than for its psychiatric indication) should be weighed against the monitoring burden. Tirzepatide 15 mg achieves approximately 20% weight loss at 72 weeks. [4] Adding bupropion-naltrexone (Contrave) produced approximately 6.1% additional weight loss above placebo in the COR-II trial (N=1,496). [7] Whether that incremental benefit justifies the additional pharmacological complexity is a case-by-case clinical decision.